Global Polidocanol Injection Market Strategic Research Report

Scope of the Report

The global Polidocanol Injection market size is predicted to grow from US$ 85.11 million in 2025 to US$ 141 million in 2032; it is expected to grow at a CAGR of 7.7% from 2026 to 2032.

Polidocanol injection is a therapeutic drug primarily used in sclerotherapy to address varicose veins and spider veins.

Polidocanol Injection is a widely used non-ionic surfactant-based sclerosing agent indicated primarily for the treatment of varicose veins, telangiectasias, and vascular malformations. Its mechanism of action involves direct endothelial damage upon intravascular injection, leading to endothelial cell disruption, thrombus formation, vessel fibrosis, and eventual occlusion. Polidocanol’s dual functionality as a detergent and anesthetic-like agent makes it highly favorable in modern sclerotherapy, especially when compared to older agents like hypertonic saline or absolute ethanol, which often cause significant pain and tissue irritation.

From a clinical and safety perspective, Polidocanol stands out for its low incidence of adverse reactions, including minimal injection-site pain, low risk of necrosis, and rare systemic events when properly administered. It is FDA-approved for the treatment of incompetent varicose veins and is considered the agent of choice in both liquid and foam sclerotherapy. Foam formulations, created by mixing the solution with air or gas, enhance the surface area contact within the vein, reduce dilution by blood, and allow treatment of larger veins with reduced volume, improving efficacy and reducing recurrence rates.

In regulatory and commercial terms, Polidocanol Injection is included in treatment guidelines across the US, Europe, and parts of Asia. The market is dominated by key formulations like Asclera® (Merz Pharmaceuticals) in the US and Aethoxysklerol® (Kreussler Pharma) in Europe, both backed by substantial clinical data. Generic versions are increasingly available, especially in markets with established procedural use of sclerotherapy in dermatology, phlebology, and cosmetic medicine. Its use has expanded beyond varicose veins to include vascular anomalies in children, hemorrhoid sclerotherapy, and adjunctive use in minimally invasive cosmetic procedures.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Polidocanol Injection market?

What factors are driving Polidocanol Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Polidocanol Injection market opportunities vary by end market size?

How does Polidocanol Injection break out by Type, by Application?

This report presents a comprehensive overview of the global Polidocanol Injection market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 10mg per Unit
• 20mg per Unit
• 60mg per Unit

Segment by Application

• Hospital
• Clinic
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Polidocanol Injection market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact